500 related articles for article (PubMed ID: 9014750)
1. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
2. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
4. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
5. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
6. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
7. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
8. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
12. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
13. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
14. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
15. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
16. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
17. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
[TBL] [Abstract][Full Text] [Related]
18. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
[TBL] [Abstract][Full Text] [Related]
19. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
20. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
